Bryan R. Kestenbaum

Bryan Kestenbaum practices at Harborview Medical Center in Seattle, Washington, part of University of Washington.

Bryan Kestenbaum's NPI, 1790860500, was assigned on October 27, 2006. Bryan Kestenbaum graduated from University of Massachusetts Medical School in 1995. Bryan Kestenbaum holds Washington license MD00037299.

Bryan Kestenbaum's primary practice is Harborview Medical Center, at 325 9th Avenue, Seattle, WA 98104 in King County. The practice phone is (206) 744-9535.

Bryan Kestenbaum's primary practice is Harborview Medical Center in Seattle, Washington, part of University of Washington. The medical group on file is UW Physicians. Dmand AI also links Bryan Kestenbaum to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Bryan Kestenbaum practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Bryan Kestenbaum's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Bryan Kestenbaum is licensed in Washington.

CMS data shows 124 Medicare services from Bryan Kestenbaum across 3 procedure codes in 2024, for 51 Medicare patients. Medicare paid $12,382 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 51 Medicare patients who saw Bryan Kestenbaum in 2024. The largest group is 65 to 74, with 27 patients. 75% of them have chronic kidney disease, and 75% have diabetes. 59% are also on Medicaid. Their average risk score is 6.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Bryan Kestenbaum's median patient age at 63, with 46% women.

In 2016, Bryan Kestenbaum wrote 36 Medicare Part D claims. Every claim was for a generic drug. They cover 2 drugs, with $345 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Bryan Kestenbaum for performance year 2024, reported through an alternative payment model (APM). Bryan Kestenbaum accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 240 papers to Bryan Kestenbaum, published from 2004 to 2025. 2017 was the busiest year, with 22. The most frequent topics are Renal Insufficiency, Chronic, Vitamin D and Glomerular Filtration Rate. Bryan Kestenbaum has published most often in Clin J Am Soc Nephrol. Bryan Kestenbaum's most frequent co-authors are David S. Siscovick, Jonathan Himmelfarb, MD and Joachim Hanno Ix, MD.

Dmand AI links Bryan Kestenbaum to 2 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Diabetic Nephropathies, Sarcopenia and Diabetes Complications.

CMS Open Payments shows 8 general payments to Bryan Kestenbaum from 2 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Fresenius USA Marketing, Inc. paid the most, $3,746.

Bryan Kestenbaum graduated from University of Massachusetts Medical School in 1995.